Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11717)
All Articles published online
|
Publishing Process of This Article
|
Jan 28, 2017 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23(4): 668-675 [PMID: 28216974 DOI: 10.3748/wjg.v23.i4.668] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i4/668.htm |
| Number | Citing Articles |
| 1 |
Hidetaka Okubo, Junichi Akiyama, Masao Kobayakawa, Megumi Kawazoe, Saori Mishima, Yusuke Takasaki, Naoyoshi Nagata, Takayuki Shimada, Chizu Yokoi, Shiori Komori, Kana Kimura, Yuya Hisada, Eri Iwata, Kazuhiro Watanabe, Naohiro Yanagisawa, Sho Shiroma, Akira Shimomura, Koki Okahara, Hourin Cho, Naomi Uemura. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. Journal of Gastroenterology 2020; 55(11): 1054 doi: 10.1007/s00535-020-01723-6
|
| 2 |
Amin Talebi Bezmin Abadi, Enzo Ierardi. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00316
|
| 3 |
Irene Martinucci, Corrado Blandizzi, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Santino Marchi, Nicola de Bortoli, Edoardo Savarino. Vonoprazan fumarate for the management of acid-related diseases. Expert Opinion on Pharmacotherapy 2017; 18(11): 1145 doi: 10.1080/14656566.2017.1346087
|
| 4 |
Naoyoshi Mori, Yuuki Nishiura, Daisuke Suga, Isao Moritani, Yutaka Yamanaka, Yumi Ooya, Hidekazu Inoue, Koujirou Takase, Masato Hioki, Katsuya Shiraki. Second‑line triple therapy in failures with vonoprazan‑based triple therapy for eradication of Helicobacter pylori. Biomedical Reports 2018; doi: 10.3892/br.2018.1111
|
| 5 |
Shou Quan Dong, Tikka Prabhjot Singh, Xin Wei, Huang Yao, Hong Ling Wang. Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?. Helicobacter 2017; 22(6) doi: 10.1111/hel.12438
|
| 6 |
Yuan Qiao, Jun Zhao, Xuanfeng Yue, Yang Zhang, Ruitao Zhang, Yuan Xu, Xiuling Tang, Xueying Liu, Qingwei Wang. Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry. Journal of Chromatography B 2017; 1059: 56 doi: 10.1016/j.jchromb.2017.05.013
|
| 7 |
Shasha Chen, Weina Shen, Yuhuan Liu, Qiang Dong, Yongquan Shi. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. Chinese Medical Journal 2023; 136(14): 1690 doi: 10.1097/CM9.0000000000002696
|
| 8 |
Ligang Liu, Milap C. Nahata. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. Annals of Pharmacotherapy 2023; 57(10): 1185 doi: 10.1177/10600280221149708
|
| 9 |
Satoshi Shinozaki, Hiroyuki Osawa, Hirotsugu Sakamoto, Yoshikazu Hayashi, Yasutoshi Kobayashi, Yoshimasa Miura, Alan Kawarai Lefor, Hironori Yamamoto. Pre‐treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan‐based regimen. The Kaohsiung Journal of Medical Sciences 2018; 34(8): 456 doi: 10.1016/j.kjms.2018.03.009
|
| 10 |
H. Yu. Kiselev, C. L. Gorlenko, Ya. A. El-Taravi, E. E. Porubayeva, E. V. Budanova. Modern knowledge on pathogenesis, diagnosis and treatment of helicobacter infection. Experimental and Clinical Gastroenterology 2021; (9): 15 doi: 10.31146/1682-8658-ecg-193-9-15-26
|
| 11 |
Y. S. Jung, E. H. Kim, C. H. Park. Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2017; 46(2): 106 doi: 10.1111/apt.14130
|
| 12 |
Anthony O'Connor, Dominique Lamarque, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017; 22(S1) doi: 10.1111/hel.12410
|
| 13 |
Mitsushige Sugimoto, Yoshio Yamaoka. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Frontiers in Pharmacology 2019; 9 doi: 10.3389/fphar.2018.01560
|
| 14 |
Chen Chen, Daya Zhang, Shimei Huang, Fan Zeng, Da Li, Xiaodong Zhang, Runxiang Chen, Shiju Chen, Jun Wang, Feihu Bai. Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03225-8
|
| 15 |
Vasiliy Ivanovich Reshetnyak, Tatiana Magomedalievna Reshetnyak. Significance of dormant forms of <i>Helicobacter pylori</i> in ulcerogenesis. World Journal of Gastroenterology 2017; 23(27): 4867-4878 doi: 10.3748/wjg.v23.i27.4867
|
| 16 |
Muhammad Miftahussurur, Boby Pratama Putra, Yoshio Yamaoka. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals 2020; 13(10): 276 doi: 10.3390/ph13100276
|
| 17 |
Xiaoduan Zhuang, Huiyue Jiang, Dandan Jin, Meiling Sun, Zhenwu Wang, Xinying Wang. The efficacy and safety of vonoprazan in quadruple therapy for Helicobacter pylori eradication: a comparative study. Gastroenterology Report 2023; 12 doi: 10.1093/gastro/goae036
|
| 18 |
Yousef Abdel‐Aziz, David C. Metz, Colin W. Howden. Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders. Alimentary Pharmacology & Therapeutics 2021; 53(7): 794 doi: 10.1111/apt.16295
|
| 19 |
Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda, Sho Suzuki. Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for <i>Helicobacter pylori</i>. Open Journal of Gastroenterology 2017; 7(09): 243 doi: 10.4236/ojgas.2017.79026
|
| 20 |
J.-D. de Korwin. Helicobacter pylori : quand rechercher une infection et la traiter chez l’adulte ?. La Revue de Médecine Interne 2021; 42(7): 482 doi: 10.1016/j.revmed.2020.11.012
|
| 21 |
Haruhiko Ozaki, Satoshi Harada, Toshihisa Takeuchi, Shinpei Kawaguchi, Yoshiaki Takahashi, Yuichi Kojima, Kazuhiro Ota, Yasushi Hongo, Kiyoshi Ashida, Masahiro Sakaguchi, Satoshi Tokioka, Hiroki Sakamoto, Takahisa Furuta, Kazunari Tominaga, Kazuhide Higuchi. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 2018; 97(3): 212 doi: 10.1159/000485097
|
| 22 |
Hideki Mori, Hidekazu Suzuki, Fumio Omata, Tatsuhiro Masaoka, Daisuke Asaoka, Kohei Kawakami, Shigeaki Mizuno, Naoto Kurihara, Akihito Nagahara, Nobuhiro Sakaki, Masayoshi Ito, Yo Kawamura, Masayuki Suzuki, Yuji Shimada, Hitoshi Sasaki, Takeshi Matsuhisa, Akira Torii, Toshihiro Nishizawa, Tetsuya Mine, Toshifumi Ohkusa, Takashi Kawai, Kengo Tokunaga, Shin’ichi Takahashi. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therapeutic Advances in Gastroenterology 2019; 12: 175628481985851 doi: 10.1177/1756284819858511
|
| 23 |
Tomoari Kamada, Kiichi Satoh, Toshiyuki Itoh, Masanori Ito, Junichi Iwamoto, Tadayoshi Okimoto, Takeshi Kanno, Mitsushige Sugimoto, Toshimi Chiba, Sachiyo Nomura, Mitsuyo Mieda, Hideyuki Hiraishi, Junji Yoshino, Atsushi Takagi, Sumio Watanabe, Kazuhiko Koike. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. Journal of Gastroenterology 2021; 56(4): 303 doi: 10.1007/s00535-021-01769-0
|
| 24 |
Haiying Gong, Di Han, Sen Liu, Chengjiang Liu, Xiaolin Zhu, Diping Chen. Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis. Revista Española de Enfermedades Digestivas 2022; doi: 10.17235/reed.2022.9228/2022
|
| 25 |
Yohei Horikawa, Hiroya Mizutamari, Nobuya Mimori, Yuhei Kato, Saki Fushimi, Sayaka Sato, Syunji Okubo. Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis. Scandinavian Journal of Gastroenterology 2018; 53(2): 243 doi: 10.1080/00365521.2017.1410569
|
| 26 |
Soichiro Sue, Shin Maeda. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?. Gut and Liver 2021; 15(6): 799 doi: 10.5009/gnl20242
|
| 27 |
Wentao Xu, Zhaohui Bai, Yiyang Shang, Jing Wang, Yujun Wong, Xingshun Qi. Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311678 doi: 10.1177/17562848231167858
|
| 28 |
Takahiro Suzuki, Takuma Kagami, Takahiro Uotani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, Takahisa Furuta. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. European Journal of Clinical Pharmacology 2018; 74(1): 45 doi: 10.1007/s00228-017-2324-1
|